Source: International Congress 2018 – New developments in the treatment of asthma
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
K. Murphy (Boys Town, United States of America), R. Noble (Malvern, United States of America), L. Hickey (Malvern, United States of America), M. Garin (Malvern, United States of America). Efficacy of weight-based reslizumab dosing is consistent across body weights in post-hoc analysis. 1026

Member's Comments

No comment yet.

Related content which might interest you: Efficacy of aclidinium/formoterol: pooled post hoc analysis of patients naïve to COPD maintenance therapy Source: International Congress 2017 – COPD management Year: 2017 Symptom improvement over time with umeclidinium/vilanterol versus monotherapy: a post-hoc analysis of the EMAX trial Source: International Congress 2019 – COPD clinical trials: inhaled and oral therapies Year: 2019 Improvements in lung function with umeclidinium/vilanterol analysed by reversibility at screening: a post hoc analysis of the EMAX trial Source: Virtual Congress 2021 – Inhaled treatments for COPD: clinical trials and real-world studies Year: 2021 Reduction in asthma exacerbations with indacaterol/glycopyrronium/mometasone high-dose versus medium-dose: a post hoc analysis from the IRIDIUM study Source: Virtual Congress 2020 – Asthma and cough: clinical trials and pharmacological insights Year: 2020 Adjustable dosing with budesonide/formoterol in a single inhaler reduces costs compared with a conventional fixed dosing regimen Source: Eur Respir J 2003; 22: Suppl. 45, 411s Year: 2003 Mometasone/ indacaterol/ glycopyrronium demonstrates similar efficacy in men and women: post hoc analysis of IRIDIUM study Source: Virtual Congress 2021 – Asthma inhalers: new devices and adherence Year: 2021 Effect of triple therapy with extra-fine BDP/FF/GB pMDI during seasonal peaks of asthma exacerbations. A post-hoc analysis of the TRIMARAN and TRIGGER studies Source: Virtual Congress 2020 – Inhaled corticosteroids and bronchodilator studies in asthma Year: 2020 Circulating desmosine as a biomarker of azithromycin treatment response: a post hoc analysis of the COLUMBUS randomised controlled trial Source: ERJ Open Res, 4 (4) 00136-2018; 10.1183/23120541.00136-2018 Year: 2018 Cost-effectiveness of tiotropium versus salmeterol: A trial-based analysis followed by a model-based extrapolation Source: Annual Congress 2011 - Understanding the burden of chronic respiratory diseases: what decision makers need to know Year: 2011 Characterising patients with COPD by baseline short-acting ß2-agonist (SABA) use: a post hoc analysis of the EMAX trial Source: Virtual Congress 2020 – Clinical studies of COPD: combination inhalers and much more Year: 2020 Efficacy of different dosing regimens of azithromycin in a real-world severe asthma cohort Source: Virtual Congress 2021 – Advances in asthma treatment Year: 2021 Managed adjustable dosing of budesonide/formoterol combination provides equivalent asthma control to fixed dosing at a lower overall dose Source: Eur Respir J 2002; 20: Suppl. 38, 396s Year: 2002 Once-daily QVA149 improves dyspnoea and health status compared with tiotropium plus formoterol in patients without ICS use: A post-hoc analysis of the QUANTIFY study Source: International Congress 2015 – New data on established treatments for asthma and COPD Year: 2015 Predictors of loss of asthma control in the Phase 2a INCONTRO trial: A post-hoc analysis Source: Virtual Congress 2020 – Asthma and cough: clinical trials and pharmacological insights Year: 2020 Managed adjustable dosing of budesonide/formoterol combination is similarly well tolerated to fixed dosing Source: Eur Respir J 2002; 20: Suppl. 38, 42s Year: 2002 Cost-effectiveness of the fixed-dose combination tiotropium + olodaterol based on the DYNAGITO trial results Source: International Congress 2018 – COPD, asthma and tuberculosis: benefits related to therapy costs Year: 2018 Adjustable maintenance dosing with budesonide/formoterol provides effective asthma symptom control at a lower average dose than fixed dosing: results of a study in Italy Source: Eur Respir J 2003; 22: Suppl. 45, 411s Year: 2003 Use of a novel Bayesian borrowing statistical method to assess efficacy of mepolizumab in adolescents Source: Virtual Congress 2020 – Paediatric asthma Year: 2020 Adjustable maintenance dosing with budesonide/formoterol provides effective asthma symptom control at a lower average dose than with fixed dosing – 6-month study Source: International Congress 2018 – Asthma and drugs Year: 2018 Population pharmacokinetic and exposure-response analyses to support fixed dosing of tezepelumab in patients with severe asthma Source: Virtual Congress 2021 – Asthma clinical trials and real-life studies Year: 2021